PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity

Published:2018-08-14 Issue:10 Volume:103 Page:3589-3592
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Akturk Halis Kaan¹,Alkanani Aimon¹,Zhao Zhiyuan¹,Yu Liping¹,Michels Aaron W¹^ORCID

Affiliation:

1. Barbara Davis Center for Diabetes, University of Colorado, School of Medicine, Aurora, Colorado

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/103/10/3589/25902898/jc.2018-01430.pdf

Reference13 articles.

1. Immune-related adverse events associated with immune checkpoint blockade;Postow;N Engl J Med,2018

2. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab;Menzies;Ann Oncol,2017

3. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease;Danlos;Eur J Cancer,2018

4. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies;Byun;Nat Rev Endocrinol,2017

5. Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes;Mellati;Diabetes Care,2015

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine toxicity of cancer immunotherapy;International Journal of Molecular and Immuno Oncology;2024-08-31

2. Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients;Cancers;2024-07-26

3. Pembrolizumab autoimmune related diabetes: Moving forward, keep learning;World Journal of Clinical Oncology;2024-05-24

4. Experience with pembrolizumab in a renal transplant patient with advanced lung cancer: a case report and review;Anti-Cancer Drugs;2024-03-08

5. Experience with pembrolizumab in a renal transplant patient with advanced lung cancer: a case report and review;Anti-Cancer Drugs;2024-01-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3